Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VINCENT trial of venetoclax + azacitidine versus intensive chemotherapy in newly diagnosed NPM1-mutated AML
2024-515267-59-00Phase 2Authorised
- Sponsor
- Technische Universität Dresden
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Technische Universität Dresden. Primary endpoints: Modified event-free survival, Primary induction failure and 3 more. Planned start Apr 2024; status: authorised.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-515267-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515267-59-00.